
Sandoz Introduces Biosimilar Pyzchiva (Ustekinumab) in the US: A New Treatment Option for Approximately 12 Million Patients
Sandoz Launches Pyzchiva®: A New Biosimilar Medicine for Chronic Inflammatory Diseases in the US Sandoz, a leading global company in the field of generic and biosimilar medicines, has recently announced the launch of Pyzchiva® (ustekinumab-ttwe) in the US market. This biosimilar medicine, which is a close copy of Stelara® (ustekinumab), is used for the treatment…